Clinical trials: Rare Cancer, open to volunteers
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Cancer, NGS
Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients
As part of the French Genomic Medicine Plan 2025 (FGM), the SeqOIA and AURAGEN platforms were selected to perform high-throughput genomic sequencing.
- Conditions
- Cancer, NGS, Tumor, RARE DISEASE
- Trial name
- SONCO (NCT07147465)
- Where
- 3 sites in France
- Volunteers
- 3,149 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Myasthenia Gravis
Integrating Art Therapy and Adapted Physical Activity: Toward Improved Quality of Life in Patients With Myasthenia Gravis
Myasthenia Gravis (MG) is a rare neuromuscular disease characterized by fluctuating muscle weakness and excessive fatigability. Although medical treatments have improved, MG continues to significantly impact patients' physical…
- Trial name
- APART-MG (NCT07125105)
- Testing
- Adapted Physical Activity Only, Adapted Physical Activity + Art Therapy
- Where
- France
- Volunteers
- 102 people
- Sponsor
- Universite du Littoral Cote d'Opale
Metastatic Myxoid Liposarcoma, Metastatic Synovial Sarcoma
Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers
This phase II trial studies how well brenetafusp (IMC-F106C) works in treating patients with preferentially expressed antigen of melanoma (PRAME) positive synovial sarcoma and myxoid/round cell liposarcoma that has spread from…
- Conditions
- Metastatic Myxoid Liposarcoma, Metastatic Synovial Sarcoma, Unresectable Myxoid Liposarcoma, Unresectable Synovial Sarcoma
- Trial name
- NCT07686367
- Testing
- Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C, Biopsy Procedure, Biospecimen Collection
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Embryonal Tumor
Rare Embryonal Tumors of the Central Nervous System: International Registry
Central nervous system (CNS) tumors are the most common solid malignancies among children. Although some types of CNS tumors like medulloblastomas and low-grade gliomas are widespread and well-studied, there is a huge number of…
- Trial name
- NCT05711992
- Where
- 11 sites in Armenia, Canada and 7 more
- Volunteers
- 300 people
- Sponsor
- Immune Oncology Research Institute
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
This clinical trial is looking at a drug called alectinib. Alectinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770037)
- Testing
- Alectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
This clinical trial is looking at a drug called atezolizumab. Atezolizumab is approved as standard of care treatment for adult patients with urothelial cancer, non-small cell lung cancer, extensive-stage small cell lung cancer…
- Conditions
- Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770102)
- Testing
- Atezolizumab
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Urothelial Cancer, Bladder Cancer
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Background: Tumors in the genitourinary tracts can occur in the kidney, bladder, prostate, and testicles and can have common and rare histologies. Some cancers that occur along the genitourinary (GU) tract are rare.
- Conditions
- Urothelial Cancer, Bladder Cancer, Genitourinary Cancer, Urogenital Neoplasms
- Trial name
- NCT04923178
- Where
- United States
- Volunteers
- 1,100 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma
A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
The purpose of the study is to find out if pembrolizumab is a useful treatment that causes few or mild side effects in people with ultra-rare sarcoma.
- Trial name
- NCT07089992
- Testing
- Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sarcoma, Malignant Mesenchymoma
The Sarcoma Biology and Outcome Project
SarcBOP - An interdisciplinary and translational registry SarcBOP aims to establish a database that integrates every aspect possibly relevant to sarcoma treatment and research.
- Conditions
- Sarcoma, Malignant Mesenchymoma, Sarcoma of Bone and Connective Tissue
- Trial name
- SarcBOP (NCT04758325)
- Where
- Germany
- Volunteers
- 3,000 people
- Sponsor
- Prof. Dr. Richard F Schlenk
Malignant Female Reproductive System Neoplasm, Metastatic Malignant Female Reproductive System Neoplasm
Influencing Next-Generation Oncologic Outcomes Through Rapid Integration of Functional Precision Medicine (NOORI): A Feasibility Study of SmartMatch in Rare Gynecologic Cancers
This study is being done to determine how easy it is to use standard of care (SOC) surgical resections or biopsy for SmartMatch analysis to determine treatment options in advanced gynecological malignancies.
- Conditions
- Malignant Female Reproductive System Neoplasm, Metastatic Malignant Female Reproductive System Neoplasm, Unresectable Malignant Female Reproductive System Neoplasm
- Trial name
- NCT07731880
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
NSCLC (Non-small Cell Lung Carcinoma), Stage III
Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma
This is a prospective, single-arm, Phase II clinical study aimed at evaluating the efficacy and safety of 160mg fimonertinib in combination with definitive radiotherapy for patients with EGFR uncommon driver mutation-positive…
- Conditions
- NSCLC (Non-small Cell Lung Carcinoma), Stage III, EGFR Uncommon Mutations
- Trial name
- NCT07314216
- Testing
- Firmonertinib, Definitive Thoracic Radiotherapy
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Hunan Cancer Hospital
Anemia, Bone Marrow Failure
European Rare Blood Disorders Platform (ENROL)
ENROL, the European Rare Blood Disorders Platform has been conceived in the core of ERN-EuroBloodNet as an umbrella for both new and already existing registries on Rare Hematological Diseases (RHDs).
- Conditions
- Anemia, Bone Marrow Failure, Bleeding Disorder, Iron Metabolism Disorders
- Trial name
- ENROL (NCT06250595)
- Testing
- Collection of clinical and laboratory data from EHR.
- Where
- Spain
- Volunteers
- 37,090 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Rare Cancer
Treatment Guided by Comprehensive Genome and Transcriptome Analysis Versus Standard of Care in Advanced Rare Cancers
Rare cancers, defined by an incidence of fewer than 6 cases per 100,000 persons per year, constitute nearly 25% of adult malignancies.
- Trial name
- RATIONALE (NCT06855134)
- Where
- 16 sites in Germany
- Volunteers
- 946 people
- Sponsor
- German Cancer Research Center
Advanced Solid Tumor
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or…
- Trial name
- NCT07070232
- Testing
- BNT326, Pumitamig, Itraconazole
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 1,438 people
- Sponsor
- BioNTech SE
Prader-Willi Syndrome, PWS-like Syndrome
GROWing Up With Rare GENEtic Syndromes
Introduction Rare complex syndromes Patients with complex genetic syndromes, by definition, have combined medical problems affecting multiple organ systems, and intellectual disability is often part of the syndrome.
- Conditions
- Prader-Willi Syndrome, PWS-like Syndrome, Silver Russel Syndrome, Congenital Hypopituitarism
- Trial name
- GROW UR GENES (NCT04463316)
- Testing
- Retrospective file studies
- Where
- Netherlands
- Volunteers
- 600 people
- Sponsor
- dr. Laura C. G. de Graaff-Herder
Urologic Diseases, Male Infertility
Protocol N. 2014 - Observational Study on the Quality of Life of Outpatients
Prospective observational study on the quality of life of patients attending general urology, sexual medicine, reproductive medicine, functional urology, neuro-urology and uro-oncology clinics.The data relating to the clinical…
- Conditions
- Urologic Diseases, Male Infertility, Sexual Medicine
- Trial name
- NCT06193850
- Testing
- Observation during time
- Where
- Italy
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Urachal Cancer, Advanced Solid Tumor Cancer
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies
This study is a single-center, multi-cohort, phase II clinical trial. Eligible patients with HER2-positive advanced solid tumors were enrolled after providing informed consent.
- Conditions
- Urachal Cancer, Advanced Solid Tumor Cancer, Antibody-drug Conjugates
- Trial name
- NCT07309770
- Testing
- SHR-A1811, Trastuzumab Rezetecan
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sheng Zhang
Rare Cancer
Registry Study on Rare Cancers in Korea
This study aims to determine the participation rate of patients with registered rare cancers in clinical research.
- Trial name
- rarecancer (NCT06746766)
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Yonsei University
CADASIL, Cavernous Angioma
Biological Collection of the Rare Diseases of the Brain and Eye Vessels Cohort - 2
CERVCO is the French National Reference Centre for Rare Cerebrovascular and Retinal Diseases, accredited by the Ministry of Health since 2005.
- Conditions
- CADASIL, Cavernous Angioma, Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy, Small Vessel Disease
- Trial name
- B-MRVC2 (NCT07650110)
- Testing
- Biocollection, Neurological evaluation and Biocollection
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris